218 related articles for article (PubMed ID: 37403358)
21. Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment.
Kim SM; Shin SC; Kim EE; Kim SH; Park K; Oh SJ; Jang M
ACS Nano; 2018 Aug; 12(8):7750-7760. PubMed ID: 30028587
[TBL] [Abstract][Full Text] [Related]
22. Lentiviral Capsid-Mediated
Lu Z; Yao X; Lyu P; Yadav M; Yoo K; Atala A; Lu B
CRISPR J; 2021 Dec; 4(6):914-928. PubMed ID: 33733873
[TBL] [Abstract][Full Text] [Related]
23. Delivery of CRISPR-Cas12a Ribonucleoprotein Complex for Genome Editing in an Embryogenic Citrus Cell Line.
Fang H; Culver JN; Niedz RP; Qi Y
Methods Mol Biol; 2023; 2653():153-171. PubMed ID: 36995625
[TBL] [Abstract][Full Text] [Related]
24. A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System.
Bellizzi A; Ahye N; Jalagadugula G; Wollebo HS
J Neuroimmune Pharmacol; 2019 Dec; 14(4):578-594. PubMed ID: 31512166
[TBL] [Abstract][Full Text] [Related]
25. A carrier-free multiplexed gene editing system applicable for suspension cells.
Ju A; Lee SW; Lee YE; Han KC; Kim JC; Shin SC; Park HJ; EunKyeong Kim E; Hong S; Jang M
Biomaterials; 2019 Oct; 217():119298. PubMed ID: 31280073
[TBL] [Abstract][Full Text] [Related]
26. Scaffold-Based Delivery of CRISPR/Cas9 Ribonucleoproteins for Genome Editing.
Chooi WH; Chin JS; Chew SY
Methods Mol Biol; 2021; 2211():183-191. PubMed ID: 33336278
[TBL] [Abstract][Full Text] [Related]
27. Genome editing using preassembled CRISPR-Cas9 ribonucleoprotein complexes in Fusarium graminearum.
Lee N; Park J; Kim JE; Shin JY; Min K; Son H
PLoS One; 2022; 17(6):e0268855. PubMed ID: 35657788
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
29. CRISPR based targeted genome editing of Chlamydomonas reinhardtii using programmed Cas9-gRNA ribonucleoprotein.
Dhokane D; Bhadra B; Dasgupta S
Mol Biol Rep; 2020 Nov; 47(11):8747-8755. PubMed ID: 33074412
[TBL] [Abstract][Full Text] [Related]
30. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
31. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
32. Genome editing reagent delivery in plants.
Ghogare R; Ludwig Y; Bueno GM; Slamet-Loedin IH; Dhingra A
Transgenic Res; 2021 Aug; 30(4):321-335. PubMed ID: 33728594
[TBL] [Abstract][Full Text] [Related]
33. Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination.
Martin RM; Ikeda K; Cromer MK; Uchida N; Nishimura T; Romano R; Tong AJ; Lemgart VT; Camarena J; Pavel-Dinu M; Sindhu C; Wiebking V; Vaidyanathan S; Dever DP; Bak RO; Laustsen A; Lesch BJ; Jakobsen MR; Sebastiano V; Nakauchi H; Porteus MH
Cell Stem Cell; 2019 May; 24(5):821-828.e5. PubMed ID: 31051134
[TBL] [Abstract][Full Text] [Related]
34. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
Muramoto T; Iriki H; Watanabe J; Kawata T
Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
[TBL] [Abstract][Full Text] [Related]
36. Establishment of a PEG-mediated protoplast transformation system based on DNA and CRISPR/Cas9 ribonucleoprotein complexes for banana.
Wu S; Zhu H; Liu J; Yang Q; Shao X; Bi F; Hu C; Huo H; Chen K; Yi G
BMC Plant Biol; 2020 Sep; 20(1):425. PubMed ID: 32933485
[TBL] [Abstract][Full Text] [Related]
37. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping.
Gee P; Lung MSY; Okuzaki Y; Sasakawa N; Iguchi T; Makita Y; Hozumi H; Miura Y; Yang LF; Iwasaki M; Wang XH; Waller MA; Shirai N; Abe YO; Fujita Y; Watanabe K; Kagita A; Iwabuchi KA; Yasuda M; Xu H; Noda T; Komano J; Sakurai H; Inukai N; Hotta A
Nat Commun; 2020 Mar; 11(1):1334. PubMed ID: 32170079
[TBL] [Abstract][Full Text] [Related]
38. Coassembly of nucleus-targeting gold nanoclusters with CRISPR/Cas9 for simultaneous bioimaging and therapeutic genome editing.
Tao Y; Yi K; Hu H; Shao D; Li M
J Mater Chem B; 2021 Jan; 9(1):94-100. PubMed ID: 33220661
[TBL] [Abstract][Full Text] [Related]
39. Two Distinct Approaches for CRISPR-Cas9-Mediated Gene Editing in Cryptococcus neoformans and Related Species.
Wang P
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898980
[No Abstract] [Full Text] [Related]
40. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
